Centro de Referencia para Lactobacilos (CERELA-CONICET), Chacabuco 145, (T4000ILC) San Miguel de Tucumán, Tucumán, Argentina.
Food Funct. 2022 Aug 1;13(15):8056-8067. doi: 10.1039/d2fo01195f.
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by deterioration and loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc), resulting in motor deficits. Many studies have revealed an inverse relationship between thiamine consumption and susceptibility to PD. Previously, (.) CRL 1905 was selected as thiamine-producing lactic acid bacteria (LAB), and its amprolium-resistant clone, CRL 1905*, was able to produce higher levels of this vitamin and inhibited neuronal death in an model. The present work aimed to evaluate the neuroprotective effect of these thiamine-producing LAB in an parkinsonian mouse model. Male C57BL/6 mice injected with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) were orally administered with one of the LAB strains or commercial thiamine for 1 month. The administration of either thiamine-producing LAB prevented the motor deficits of mice similar to the effects of the commercial vitamin. These benefits were associated with increased number of tyrosine hydroxylase positive (TH+) neurons in the SNpc. The evaluation of the inflammatory response caused by the neurotoxin showed that both LAB decreased pro-inflammatory cytokines in serum; moreover, the strain selected as the higher thiamine producer showed the best anti-inflammatory effect locally in the brain and significantly decreased the levels of IL-6, TNF-α, IFN-γ and MCP-1, which remained similar to the levels of healthy control animals. These results demonstrated that thiamine-producing CRL 1905* has the potential to be used as part of a strategy to prevent or to complement the treatments of neurodegenerative diseases such as PD. A limitation of this study is that we cannot guarantee whether LAB are capable of producing thiamine in the intestinal tract or release the vitamin after lysis; however, the results show that thiamine production by CRL 1905 is implicated in the observed effect, in addition to other benefits associated with the LAB strain that are also involved and are currently under study.
帕金森病（PD）是一种进行性神经退行性疾病，其特征是黑质致密部（SNpc）中的多巴胺能神经元退化和丧失，导致运动功能障碍。许多研究表明，硫胺素消耗与 PD 的易感性之间存在反比关系。此前，（……）CRL 1905 被选为产硫胺素乳酸菌（LAB），其抗氨丙啉的克隆株 CRL 1905能够产生更高水平的这种维生素，并抑制模型中的神经元死亡。本工作旨在评估这些产硫胺素 LAB 在帕金森病小鼠模型中的神经保护作用。雄性 C57BL/6 小鼠注射 1-甲基-4-苯基-1,2,3,6-四氢吡啶（MPTP）后，用其中一种 LAB 菌株或商业硫胺素口服给药 1 个月。产硫胺素 LAB 的给药可预防小鼠的运动功能障碍，类似于商业维生素的作用。这些益处与 SNpc 中酪氨酸羟化酶阳性（TH+）神经元数量的增加有关。对神经毒素引起的炎症反应的评估表明，两种 LAB 均降低了血清中的促炎细胞因子；此外，作为产硫胺素较高的菌株表现出了最佳的局部抗炎作用，并且大脑中 IL-6、TNF-α、IFN-γ 和 MCP-1 的水平显著降低，与健康对照动物的水平相似。这些结果表明，产硫胺素的 CRL 1905具有作为预防或补充 PD 等神经退行性疾病治疗策略的一部分的潜力。本研究的一个局限性是我们不能保证 LAB 是否能够在肠道中产生硫胺素或在裂解后释放维生素；然而，结果表明 CRL 1905 的硫胺素产生与观察到的效应有关，此外，与 LAB 菌株相关的其他益处也涉及到，目前正在研究中。
